scholarly journals Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases

2020 ◽  
Vol 13 (5) ◽  
pp. 405-418
Author(s):  
Rakeeb Kureshi ◽  
Angela Zhu ◽  
Jikui Shen ◽  
Stephany Y. Tzeng ◽  
Leilani R. Astrab ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Molecular Engineering ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Factor Antagonist

scholarly journals Updates in Retinal Diseases 2018

2018 ◽  
Vol 12 (1) ◽  
pp. 19
Author(s):  
Maurizio Battaglia Parodi ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Vision Loss ◽  
Choroidal Neovascularisation ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Expert Interview ◽  
The University ◽  
Endothelial Growth Factor

Choroidal neovascularisation (CNV) is a major cause of vision loss. For more than 10 years, intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs have been used in the treatment of CNV. While effective, this treatment strategy is limited by the injection burden. Most patients require multiple injections and response levels can vary. Early diagnosis and treatment of CNV can increase the success rate of treatment. There is, therefore, considerable interest in identifying biomarkers both to identify patients most likely to respond to treatment and to facilitate early detection of the condition. In an expert interview, Maurizio Battaglia Parodi of the University Vita-Salute Milan, Italy, discusses the latest advances in CNV.

scholarly journals Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Shivi Agrawal ◽  
Malav Joshi ◽  
John B. Christoforidis
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Safety Profile ◽  
Intravitreal Injections ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Vital Importance ◽  
Anti Vegf ◽  
Endothelial Growth Factor ◽  
Ocular Safety

Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs

2021 ◽  
Vol 49 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Christina Kaiser Marko ◽  
Joan W. Miller
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Photodynamic Therapy ◽  
Growth Factor ◽  
Age Related Macular Degeneration ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Pharmacological Treatments ◽  
Age Related ◽  
Wide Range ◽  
Endothelial Growth Factor

AbstractThe development of photodynamic therapy and anti-vascular endothelial growth factor agents have revolutionized the treatment of retinal diseases, transforming the retina subspecialty by ushering in an age of pharmacological treatments for a wide range of diseases, including age-related macular degeneration (AMD).

Sign in / Sign up

Export Citation Format

Share Document